TriSalus Life Sciences, Inc. TLSI

TriSalus Life Sciences (NASDAQ:TLSI) shares rose 15. 6% in pre-market trading after the company announced that the U.

WESTMINSTER, Colo., September 22, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery™ (PEDD) portfolio.

WESTMINSTER, Colo., August 31, 2026--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

TriSalus Life Sciences Inc (TLSI) reiterates full-year guidance as reimbursement breakthrough in office-based labs and robust clinical pipeline position the company for accelerated back-half growth.

DENVER, August 06, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update.

WESTMINSTER, Colo., July 29, 2026--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings on T

WESTMINSTER, Colo., July 16, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the res

WESTMINSTER, Colo., June 10, 2026--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced it will host a virtual key opinion leader (KOL) event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly published real-world outcomes study demonstrating that Pressure-Enabled Dru

TriSalus Life Sciences Inc (TLSI) navigates commercial growth and FDA delays while showcasing improved margins and robust clinical data.

Moby summary of TriSalus Life Sciences, Inc.'s Q1 2026 earnings call

TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of +12.50% and -15.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?